Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib ...Middle East

The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency LEIDEN, The Netherlands, Sept. 28, 2022 /PRNewswire/ -- Pharming Group N.V....

Read More Details
Finally We wish PressBee provided you with enough information of ( Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib )

Also on site :

• ‘This is about more than burgers and fries’: Boycott of McDonald’s to begin this week
• Numbrix 9 - June 24
• ForexLive Asia-Pacific FX news wrap: Trump announces an Iran-Israel ceasefire